KRAS mutation testing in colorectal cancer

Advances in Anatomic Pathology

Volumn 16, Issue 4, 2009, Pages 196-203

  Plesec, Thomas P ^a   Hunt, Jennifer L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical specimens; Colorectal cancer; EGFR; KRAS; Reporting; Testing

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DNA; DNA POLYMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; RAS PROTEIN;

ALLELE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CODON; COLON RESECTION; COLORECTAL CANCER; COLORECTAL CARCINOMA; DNA EXTRACTION; DRUG COST; EXON; FOOD AND DRUG ADMINISTRATION; GEL ELECTROPHORESIS; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNOHISTOCHEMISTRY; KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG; LYMPH NODE METASTASIS; MONOTHERAPY; ONCOGENE; PATHOLOGIST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM; THERAPY EFFECT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MUTATION; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 68849120567     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181a9d4ed     Document Type: Review

References (78)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
2. Ng K, Zhu AX. Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol. 2008;65:8-20. (Pubitemid 350216479)
3. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12:541-552. (Pubitemid 37222478)
4. Spano JP, Fagard R, Soria JC, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol. 2005;16:189-194. (Pubitemid 40309295)
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351:337-345. (Pubitemid 38944402)
6. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001; 92:1331-1346.
7. Lockhart AC, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005; 32:52-60. (Pubitemid 40250126)
8. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2009;454:233-235.
9. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006;5:928-932. (Pubitemid 44776510)
10. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
11. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.
12. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother. 2006;40:241-250. (Pubitemid 43269854)
13. Wong YN, Meropol NJ, Speier W, et al. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009; 115:2081-2091.
14. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004;351:2883. (Pubitemid 40051921)
15. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-286. (Pubitemid 40590264)
16. Tsuchihashi Z, Khambata-Ford S, Hanna N, et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med. 2005;353:208-209. (Pubitemid 41058356)
17. Vallbohmer D, Zhang W, Gordon M, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol. 2005;23: 3536-3544.
18. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810. (Pubitemid 46211358)
19. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914-4921. (Pubitemid 46630920)
20. Moroni M, Sartore-Bianchi A, Veronese S, et al. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol. 2008;9:402-403.
21. Lee GH. The Kras2 oncogene and mouse lung carcinogenesis. Med Mol Morphol. 2008;41:199-203.
22. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27:1130-1136.
23. Lea IA, Jackson MA, Li X, et al. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28:1851-1858. (Pubitemid 47504878)
24. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
25. Brink M, de Goeij AF, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 2003;24:703-710. (Pubitemid 36592405)
26. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000;9:1193-1197. (Pubitemid 30844068)
27. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27: 2091-2096.
28. Engstrom PF. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy. 2008;28: 18S-22S.
29. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648. (Pubitemid 46548951)
30. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-515. (Pubitemid 351325672)
31. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer. 2007;96:1166-1169. (Pubitemid 46625066)
32. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26: 5705-5712.
33. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
34. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008; 26:374-379. (Pubitemid 351171687)
35. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
36. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
37. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
38. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-671.
39. Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83-89. (Pubitemid 351920237)
40. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008;68:1953-1961.
41. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20: 84-90.
42. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851-1857.
43. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-1145. (Pubitemid 47587019)
44. Ries LAG, Krapcho M, Stinchcomb DG, et al, eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, available at http://seer.cancer.gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
45. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer. 2009;100:1087-1094.
46. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26:4217-4219.
47. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270-1275.
48. Zauber P, Sabbath-Solitare M, Marotta SP, et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol. 2003;56: 137-140.
49. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14:4830-4835.
50. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer. 1992;52:30-33.
51. Losi L, Benhattar J, Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer. 1992;28A:1115-1120.
52. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007;26:158-163. (Pubitemid 46067341)
53. Samowitz WS. Genetic and epigenetic changes in colon cancer. Exp Mol Pathol. 2008;85:64-67.
54. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226-235. (Pubitemid 40070814)
55. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
56. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64: 8919-8923. (Pubitemid 39665498)
57. Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med. 2004;128:1372-1378. (Pubitemid 39627474)
58. Hunt JL. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch Pathol Lab Med. 2008;132: 248-260.
59. Trusky CL, Sepulveda AR, Hunt JL. Assessment of microsatellite instability in very small microdissected samples and in tumor samples that are contaminated with normal DNA. Diagn Mol Pathol. 2006;15:63-69.
60. Lim EH, Zhang SL, Li JL, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4:12-21.
61. Wang F, Wang L, Briggs C, et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn. 2007;9:441-451. (Pubitemid 47434110)
62. Coskun S, Alsmadi O. Whole genome amplification from a single cell: a new era for preimplantation genetic diagnosis. Prenat Diagn. 2007;27:297-302. (Pubitemid 46597905)
63. Balogh K, Patocs A, Majnik J, et al. Genetic screening methods for the detection of mutations responsible for multiple endocrine neoplasia type 1. Mol Genet Metab. 2004;83:74-81. (Pubitemid 39311282)
64. Righetti PG, Gelfi C. Capillary electrophoresis of DNA for molecular diagnostics. Electrophoresis. 1997;18:1709-1714. (Pubitemid 27451824)
65. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977; 74:5463-5467.
66. Shampo MA, Kyle RA. Frederick Sanger - winner of 2 Nobel prizes. Mayo Clin Proc. 2002;77:212.
67. Kolata GB. The 1980 Nobel Prize in Chemistry. Science. 1980;210:887-889.
68. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7:413-421. (Pubitemid 41149657)
69. Tatsumi K, Mitani Y, Watanabe J, et al. Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn. 2008;10:520-526.
70. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer. 2008;8:142. (Pubitemid 351785125)
71. Amicarelli G, Shehi E, Makrigiorgos GM, et al. FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res. 2007;35:e131. (Pubitemid 350111639)
72. Rouleau E, Lefol C, Bourdon V, et al. Quantitative PCR high-resolution melting (qPCR-HRM) curve analysis, a new approach to simultaneously screen point mutations and large rearrangements: application to MLH1 germline mutations in Lynch syndrome. Hum Mutat. 2009 Feb 17. [Epub ahead of print].
73. Wojcik P, Kulig J, Okon K, et al. KRAS mutation profile in colorectal carcinoma and novel mutation - internal tandem duplication in KRAS. Pol J Pathol. 2008;59:93-96. (Pubitemid 352029608)
74. Isler JA, Vesterqvist OE, Burczynski ME. Analytical validation of genotyping assays in the biomarker laboratory. Pharmacogenomics. 2007;8:353-368.
75. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin Chim Acta. 2006;363:83-94.
76. Marsh S. Pyrosequencing applications. Methods Mol Biol. 2007;373:15-24.
77. Wang L, Luhm R, Lei M. SNP and mutation analysis. Adv Exp Med Biol. 2007;593:105-116.
78. Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007; 131:852-863. (Pubitemid 46906376)